-
公开(公告)号：US20190032151A1
公开(公告)日：2019-01-31
申请号：US16157853
申请日：2018-10-11
Applicant: Genentech, Inc.
Inventor： Jeffrey Wallin , Priti Hegde
IPC: C12Q1/6886 , G01N33/574 , C07K16/22 , C07K16/28 , A61K45/06 , A61K39/395 , A61P35/00
Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, kidney cancer. The invention provides, inter alia, methods of treating cancer and methods of monitoring the response of a patient having a cancer to treatment with an anti-cancer therapy comprising a VEGF antagonist (e.g., an anti-VEGF antibody) and a PD-L1 axis binding antagonist (e.g., an anti-PD-L1 antibody).
-
公开(公告)号：US20180280408A1
公开(公告)日：2018-10-04
申请号：US15897032
申请日：2018-02-14
Applicant: Genentech, Inc.
Inventor： Marcia Belvin , Lori Friedman , Deepak Sampath , Jeffrey Wallin
IPC: A61K31/553 , A61K39/395 , G01N33/50 , C12Q1/6886 , A61K45/06 , A61K31/138 , A61K31/337 , A61K31/357 , A61K31/4196 , A61K31/437 , A61K31/4523 , A61K31/513 , A61K31/555 , A61K31/565 , A61K31/573 , A61K31/7068
Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
-
3.发明申请COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE 审中-公开AKT抑制剂化合物和化学治疗剂的组合及使用方法公开(公告)号：US20160228440A1
公开(公告)日：2016-08-11
申请号：US15017315
申请日：2016-02-05
Applicant: Genentech, Inc.
Inventor： Kui Lin , Michelle Nannini , Elizabeth Punnoose , Deepak Sampath , Jeffrey Wallin , Premal Patel
IPC: A61K31/517 , A61K31/4166
CPC classification number: A61K31/517 , A61K31/138 , A61K31/282 , A61K31/337 , A61K31/4166 , A61K31/4188 , A61K31/436 , A61K31/437 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/58 , A61K31/704 , A61K31/7068 , A61K39/3955 , A61K2039/505 , C07D239/70 , C07D403/12 , C07K16/40 , A61K2300/00
Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
Abstract translation: 本发明提供组合，其包含a）式I化合物或其药学上可接受的盐，其中R 1，R 2，R 5，R 10和A具有说明书中定义的任何值; 和b）选自5-FU，铂药剂，甲酰四氢叶酸，伊立替康，多西他赛，多柔比星，吉西他滨，SN-38，卡培他滨，替莫唑胺，紫杉醇，贝伐珠单抗，依托单抗，他莫昔芬，雷帕霉素和拉帕替尼的一种或多种药剂。 这些组合对于治疗过度增殖性疾病如癌症特别有用。
-
公开(公告)号：US10092567B2
公开(公告)日：2018-10-09
申请号：US15438277
申请日：2017-02-21
Applicant: Genentech, Inc.
Inventor： Kui Lin , Michelle Nannini , Elizabeth Punnoose , Deepak Sampath , Jeffrey Wallin , Premal Patel
IPC: A61K31/00 , A61K31/4745 , A61K31/495 , C07D239/70 , A61K31/517 , A61K31/437 , A61K31/496 , A61K31/58 , A61K31/282 , A61K31/337 , A61K31/4188 , A61K31/513 , A61K31/519 , A61K31/704 , A61K39/395 , C07D403/12 , A61K31/436 , A61K31/138 , A61K31/4166 , A61K31/555 , A61K31/7068 , C07K16/40 , A61K39/00
Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
-
公开(公告)号：US09717730B2
公开(公告)日：2017-08-01
申请号：US15017315
申请日：2016-02-05
Applicant: Genentech, Inc.
Inventor： Kui Lin , Michelle Nannini , Elizabeth Punnoose , Deepak Sampath , Jeffrey Wallin , Premal Patel
IPC: A61K31/00 , A61K31/4745 , A61K31/495 , C07D239/70 , A61K31/517 , A61K31/437 , A61K31/496 , A61K31/58 , A61K31/282 , A61K31/337 , A61K31/4188 , A61K31/513 , A61K31/519 , A61K31/704 , A61K39/395 , C07D403/12 , A61K31/436 , A61K31/138 , A61K31/4166 , A61K31/555 , A61K31/7068 , C07K16/40 , A61K39/00
CPC classification number: A61K31/517 , A61K31/138 , A61K31/282 , A61K31/337 , A61K31/4166 , A61K31/4188 , A61K31/436 , A61K31/437 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/58 , A61K31/704 , A61K31/7068 , A61K39/3955 , A61K2039/505 , C07D239/70 , C07D403/12 , C07K16/40 , A61K2300/00
Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
-
Patent Agency Ranking
6.发明申请COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND A CDK4/6 INHIBITOR COMPOUND FOR THE TREATMENT OF CANCER 审中-公开磷酸三辛酯抑制剂化合物的组合和用于治疗癌症的CDK4 / 6抑制剂化合物公开(公告)号：US20160279142A1
公开(公告)日：2016-09-29
申请号：US15080019
申请日：2016-03-24
Applicant: Genentech, Inc.
Inventor： Lori Friedman , Michelle Nannini , Deepak Sampath , Jeffrey Wallin
IPC: A61K31/553 , C12Q1/68 , A61K31/519
CPC classification number: A61K31/553 , A61K31/519 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/57415 , G01N33/57484 , G01N2333/912 , G01N2333/916 , G01N2800/52 , A61K2300/00
Abstract: Methods and compositions are provided for treating cancer in patients with a therapeutic combination comprising a therapeutically effective amounts of taselisib and palbociclib, or stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof.
Abstract translation: 提供了用于治疗患有治疗性组合的癌症的方法和组合物，所述疗法组合包含治疗有效量的替莫西立和巴布西利或其立体异构体，几何异构体，互变异构体或其药学上可接受的盐。
-
7.发明申请公开(公告)号：US20170157124A1
公开(公告)日：2017-06-08
申请号：US15438277
申请日：2017-02-21
Applicant: Genentech, Inc.
Inventor： Kui Lin , Michelle Nannini , Elizabeth Punnoose , Deepak Sampath , Jeffrey Wallin , Premal Patel
IPC: A61K31/517 , A61K31/337
CPC classification number: A61K31/517 , A61K31/138 , A61K31/282 , A61K31/337 , A61K31/4166 , A61K31/4188 , A61K31/436 , A61K31/437 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/58 , A61K31/704 , A61K31/7068 , A61K39/3955 , A61K2039/505 , C07D239/70 , C07D403/12 , C07K16/40 , A61K2300/00
Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
-
8.发明申请MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER 审中-公开磷酸三辛酯抑制剂化合物和治疗癌症的化学治疗剂的突变选择性和组合公开(公告)号：US20160045515A1
公开(公告)日：2016-02-18
申请号：US14791783
申请日：2015-07-06
Applicant: Genentech, Inc.
Inventor： Marcia Belvin , Lori Friedman , Deepak Sampath , Jeffrey Wallin
IPC: A61K31/553 , C12Q1/68 , A61K45/06
CPC classification number: A61K31/553 , A61K31/138 , A61K31/337 , A61K31/357 , A61K31/4196 , A61K31/437 , A61K31/4523 , A61K31/513 , A61K31/555 , A61K31/565 , A61K31/573 , A61K31/7068 , A61K39/39558 , A61K45/06 , A61P35/00 , C07K16/32 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/136 , C12Q2600/142 , C12Q2600/156 , C12Q2600/158 , G01N33/5011 , G01N33/5023 , A61K2300/00
Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
Abstract translation: 提供了用于治疗患有PI3K抑制剂，GDC-0032作为单一药剂或与化学治疗剂组合的患者中的过度增殖性疾病的方法和组合物。
-
9.发明授权Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer 有权磷酸肌醇3-激酶抑制剂化合物的突变选择性和组合以及用于治疗癌症的化学治疗剂公开(公告)号：US09107926B2
公开(公告)日：2015-08-18
申请号：US13912281
申请日：2013-06-07
Applicant: Genentech, Inc.
Inventor： Marcia Belvin , Lori Friedman , Deepak Sampath , Jeffrey Wallin
IPC: C07D498/00 , C07D513/00 , A61K31/553 , A61K39/395 , A61K45/06 , A61K31/138 , A61K31/337 , A61K31/357 , A61K31/4196 , A61K31/437 , A61K31/4523 , A61K31/513 , A61K31/555 , A61K31/565 , A61K31/573 , A61K31/7068 , G01N33/50 , C12Q1/68 , C07K16/32
CPC classification number: A61K31/553 , A61K31/138 , A61K31/337 , A61K31/357 , A61K31/4196 , A61K31/437 , A61K31/4523 , A61K31/513 , A61K31/555 , A61K31/565 , A61K31/573 , A61K31/7068 , A61K39/39558 , A61K45/06 , C07K16/32 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/136 , C12Q2600/142 , C12Q2600/156 , C12Q2600/158 , G01N33/5011 , G01N33/5023 , A61K2300/00
Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
Abstract translation: 提供了用于治疗患有PI3K抑制剂，GDC-0032作为单一药剂或与化学治疗剂组合的患者中的过度增殖性疾病的方法和组合物。
-
10.发明申请公开(公告)号：US20130345217A1
公开(公告)日：2013-12-26
申请号：US14012673
申请日：2013-08-28
Applicant: Genentech, Inc.
Inventor： Marcia Belvin , Lori Friedman , Klaus P. Hoeflich , Jeffrey Wallin
IPC: A61K31/5377 , A61K31/4523
CPC classification number: A61K31/5377 , A61K31/4523 , A61K31/505
Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.023 seconds)
